美国 · SEC Form 4 · 快照日期： 2026-10-18 · 构建时间： 2026-10-18 · English

美国 · SEC FORM 4

ACADIA PHARMACEUTICALS INC

ACAD · Nasdaq · CIK 0001070494 · Healthcare · Biotechnology

内部人信号

当前没有活跃买入信号

0 qualifying P purchase groups
当前 180 天评分窗口

21 同一窗口内观察到的 Form 4 交易行
9 sales · 12 期权、代扣税、授予、赠与或其他交易行

最近一次合资格买入2023-05-24 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP · $14.1M

为什么没有活跃信号？

买入活动无

近期买入无

近期卖出中等

买入信号状态未激活

评分构成

活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。

Cluster未计算

买入规模未计算

角色未计算

近期性未计算

确信度未计算

为什么没有分数？

没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。

卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct

Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER

○▼○▼○▼

Kihara JamesPRINCIPAL ACCOUNTING OFFICER

○▼▼▼

Thompson Elizabeth H.Z.EVP, Head of Research & Dev

○▼

667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPDirector,TenPercentOwner

○

Poole JonathanDirector

○

Ndu AdoraDirector

○

● 买入▼ 卖出○ 其他

Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.

买方广度、集中度与聚集买入

合资格买入进入 180 天研究窗口后，这些模块才会启用。

信号历史

暂无已记录的活跃信号快照

Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-05-24 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP.

近期 Form 4 活动

0买入

24卖出

24其他 Form 4 交易行

24SEC 申报 · 365天

买入0 qualifying P line(s) · 180 days

卖出9 sale line(s) · 仅供背景

其他12 exercise / withholding / award / gift / other lines

10b5-1／计划交易Not assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M: -31.0%
3M: -22.6%
6M: -10.1%
12M: —

波动率与流动性

波动率: 39.2%
Beta: 0.86
平均每日成交额: USD 36.1M

估值

市值: USD 3.4B
P/E: 8.9×

基本面

利润率: 36.5%
ROE: 31.9%
细分行业: Biotechnology

市场数据

价格数据截至：2026-10-04 · 价格来源：OpenBB/yfinance · 来自 SEC 申报文件：利润率, ROE · 财年截止日：2025-12-31 · 来自 Yahoo Finance：市值, P/E · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数: 8,275,918
上期报告: 9,666,972
日均成交量: 2,828,484
回补天数: 2.9

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction date	Reporting owner	类型	证券	股数	平均价格	估算金额	来源
2023-05-24	667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP	买入 (P)	Common Stock	553,263	USD 25.48	USD 14,096,156	SEC 申报 ↗
2023-05-23	667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP	买入 (P)	Common Stock	209,053	USD 25.41	USD 5,312,432	SEC 申报 ↗
2023-05-22	667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP	买入 (P)	Common Stock	134,206	USD 24.57	USD 3,297,779	SEC 申报 ↗
2020-03-18	667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP	买入 (P)	Common Stock	135,897	USD 33.52	USD 4,555,330	SEC 申报 ↗
2020-03-17	667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP	买入 (P)	Common Stock	219,800	USD 32.84	USD 7,218,880	SEC 申报 ↗
2020-03-16	667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP	买入 (P)	Common Stock	694,303	USD 31.51	USD 21,875,568	SEC 申报 ↗

Form 4 申报证据

48 transaction lines in the latest 365-day window; 405 in local history.

日期	申报人	类型	证券	股数	平均价格	估算金额	来源
2026-08-06	Schneyer Mark C.	卖出 (S)	Common Stock	14,292	USD 29.22	USD 417,627	SEC 申报 ↗
2026-08-06	Schneyer Mark C.	期权行权／转换 (M)	Common Stock	14,292	USD 17.84	USD 254,969	SEC 申报 ↗
2026-08-05	Schneyer Mark C.	卖出 (S)	Common Stock	5,849	USD 29.00	USD 169,621	SEC 申报 ↗

展开近期 Form 4 证据 (30 grouped rows)

日期	申报人	类型	证券	股数	平均价格	估算金额	来源
2026-08-06	Schneyer Mark C.	卖出 (S)	Common Stock	14,292	USD 29.22	USD 417,627	SEC 申报 ↗
2026-08-06	Schneyer Mark C.	期权行权／转换 (M)	Common Stock	14,292	USD 17.84	USD 254,969	SEC 申报 ↗
2026-08-05	Schneyer Mark C.	卖出 (S)	Common Stock	5,849	USD 29.00	USD 169,621	SEC 申报 ↗
2026-08-05	Schneyer Mark C.	期权行权／转换 (M)	Common Stock	5,849	USD 17.84	USD 104,346	SEC 申报 ↗
2026-07-30	Thompson Elizabeth H.Z.	卖出 (S)	Common Stock	16,558	USD 26.13	USD 432,663	SEC 申报 ↗
2026-07-29	Thompson Elizabeth H.Z.	期权行权／转换 (M)	Common Stock	32,272	USD —	USD —	SEC 申报 ↗
2026-06-26	Kihara James	卖出 (S)	Common Stock	11,421	USD 26.08	USD 297,860	SEC 申报 ↗
2026-05-29	667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP	奖励／授予 (A)	Common Stock	18,622	USD 0.00	USD 0	SEC 申报 ↗
2026-05-29	Poole Jonathan	期权行权／转换 (M)	Common Stock	2,010	USD —	USD —	SEC 申报 ↗
2026-05-29	Ndu Adora	期权行权／转换 (M)	Common Stock	8,107	USD —	USD —	SEC 申报 ↗
2026-05-29	HARRIGAN EDMUND	期权行权／转换 (M)	Common Stock	8,107	USD —	USD —	SEC 申报 ↗
2026-05-29	GAROFALO ELIZABETH A.	期权行权／转换 (M)	Common Stock	8,107	USD —	USD —	SEC 申报 ↗
2026-05-29	Daly James M	期权行权／转换 (M)	Common Stock	8,107	USD —	USD —	SEC 申报 ↗
2026-05-29	Brege Laura	期权行权／转换 (M)	Common Stock	8,107	USD —	USD —	SEC 申报 ↗
2026-05-26	Kihara James	卖出 (S)	Common Stock	5,401	USD 21.18	USD 114,393	SEC 申报 ↗
2026-05-04	Schneyer Mark C.	卖出 (S)	Common Stock	3,506	USD 21.79	USD 76,396	SEC 申报 ↗
2026-05-04	Kihara James	卖出 (S)	Common Stock	1,332	USD 21.79	USD 29,024	SEC 申报 ↗
2026-05-01	Schneyer Mark C.	期权行权／转换 (M)	Common Stock	6,815	USD —	USD —	SEC 申报 ↗
2026-05-01	Kihara James	期权行权／转换 (M)	Common Stock	2,596	USD —	USD —	SEC 申报 ↗
2026-04-07	Schneyer Mark C.	卖出 (S)	Common Stock	2,709	USD 22.20	USD 60,140	SEC 申报 ↗
2026-04-07	Kihara James	卖出 (S)	Common Stock	1,030	USD 22.20	USD 22,866	SEC 申报 ↗
2026-04-05	Schneyer Mark C.	期权行权／转换 (M)	Common Stock	5,276	USD —	USD —	SEC 申报 ↗
2026-04-05	Kihara James	期权行权／转换 (M)	Common Stock	2,010	USD —	USD —	SEC 申报 ↗
2026-03-26	Schneyer Mark C.	卖出 (S)	Common Stock	3,208	USD 21.65	USD 69,456	SEC 申报 ↗
2026-03-26	Kihara James	卖出 (S)	Common Stock	1,109	USD 21.65	USD 24,011	SEC 申报 ↗
2026-03-25	Thompson Elizabeth H.Z.	卖出 (S)	Common Stock	3,435	USD 21.47	USD 73,749	SEC 申报 ↗
2026-03-25	Schneyer Mark C.	卖出 (S)	Common Stock	4,177	USD 21.47	USD 89,680	SEC 申报 ↗
2026-03-25	Schneyer Mark C.	期权行权／转换 (M)	Common Stock	6,178	USD —	USD —	SEC 申报 ↗
2026-03-25	Rhodes Jennifer J	卖出 (S)	Common Stock	3,844	USD 21.47	USD 82,531	SEC 申报 ↗
2026-03-25	Owen Adams Catherine	卖出 (S)	Common Stock	11,641	USD 21.47	USD 249,932	SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期	2026-10-18
排名版本	US-v1.2
数据质量	PASS ELIGIBLE · —
股票代码	ACAD
CIK	0001070494
行业	Healthcare
细分行业	Biotechnology Yahoo Finance
SEC SIC	2834 Pharmaceutical Preparations
交易所	Nasdaq

数据覆盖

本地 Form 4 历史	405 transaction lines from 2020-01-07 to 2026-08-06 40 P purchase lines · 167 S sale lines · 198 other lines
SEC 公司申报	打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.